Paperonium

← Back to the plain-language case

Abstract reports two obesity-group odds ratios as the overweight and obesity estimates for EPT use

JAMA Netw Open (2025) · doi:10.1001/jamanetworkopen.2025.19236 · PMC12235495

Summary

The study pools 31 case-control studies to estimate associations between exogenous hormone use and intrinsic-like breast cancer subtypes, stratified by body mass index (BMI). The abstract says the associations of current estrogen-progestin therapy (EPT) use with luminal A–like and luminal B–ERBB2-like tumors "were attenuated but remained" for women with overweight (OR 1.40, 95% CI 1.02–1.92) or obesity (OR 1.68, 95% CI 1.01–2.78). In the paper's own Results text and in Supplement 1 eTable 3, both of these values come from the obesity stratum: 1.40 is the luminal A–like OR and 1.68 is the luminal B–ERBB2-like OR. The overweight estimates, 2.18 (1.83–2.61) for luminal A–like and 1.83 (1.32–2.55) for luminal B–ERBB2-like, do not appear in the abstract. No direction or significance changes, but an abstract reader would take the overweight luminal A–like excess odds to be about a third of what the paper's own data show, and would see a BMI pattern (1.40 for overweight, then 1.68 for obesity) that the full results do not show.

What the paper reports

Abstract, Results:

Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]).

Results, "Combined EPT Use and Tumor Subtypes", paragraph 2:

In women with healthy weight, current EPT users were more likely to be diagnosed with luminal A–like (OR, 2.51 [95% CI, 2.26-2.80]), luminal B–like (OR, 1.47 [95% CI, 1.17-1.86]), or luminal B–ERBB2–like (OR, 1.95 [95% CI, 1.61-2.37]) breast tumors, with significant heterogeneity across subtypes (P < .001 for heterogeneity).

Results, "Combined EPT Use and Tumor Subtypes", paragraph 3:

In women with overweight, current EPT use was positively associated with luminal A–like (OR, 2.18 [95% CI, 1.83-2.61]) and luminal B–ERBB2-like (OR, 1.83 [95% CI, 1.32-2.55]) tumors but not with other subtypes (P < .001 for heterogeneity). In women with obesity, associations for luminal A–like (OR, 1.40 [95% CI, 1.02-1.92]) and luminal B–ERBB2-like (OR, 1.68 [95% CI, 1.01-2.78]) tumors were seen, with smaller effect sizes and nonsignificant heterogeneity (P < .11 for heterogeneity).

Methods, Statistical Analysis (the only BMI definition in the paper):

To evaluate heterogeneity in associations by BMI, associations were stratified by BMI categories as follows: lean or healthy weight (hereinafter, healthy weight) (18.5-<25 [calculated as weight in kilograms divided by height in meters squared]), overweight (25-<30), or obesity (≥30).

Supplement 1, eTable 3 (EPT use by intrinsic-like subtype, stratified by BMI), "Current use" rows: Lean/normal, luminal A-like 2.51 (2.26,2.80) and luminal B-ERBB2-like 1.95 (1.61,2.37). Overweight, 2.18 (1.83,2.61) and 1.83 (1.32,2.55). Obese, 1.40 (1.02,1.92) and 1.68 (1.01,2.78).

All quotes from the article were checked verbatim against the PMC-archived text with src/show.py PMC12235495 --grep. The eTable values were read from the supplement PDF.

What the paper's own numbers show

Method. I took every current-EPT odds ratio and 95% CI for luminal A–like and luminal B–ERBB2-like tumors from the Results text, and checked that each CI is symmetric about its OR on the log scale. I checked the text values against Supplement 1 eTable 3. I then matched each (OR, lower, upper) triple in the abstract against every BMI-by-subtype cell in the Results. To size the discrepancy, I compared the abstract's "overweight" value with the paper's overweight estimates as a ratio of ORs and as excess odds (OR − 1). I computed a z statistic for the difference of log ORs, using standard errors taken from the CI widths. That z treats the overweight and obesity strata as independent, which holds because they are disjoint groups of women. All calculations are in recompute.py.txt.

Quantity Location Reported Recomputed
Healthy weight, luminal A–like Abstract; Results para. 2; eTable 3 2.51 (2.26–2.80) Abstract and Results identical; geometric CI midpoint 2.516
Healthy weight, luminal B–ERBB2-like Abstract; Results para. 2; eTable 3 1.95 (1.61–2.37) Abstract and Results identical; midpoint 1.953
Overweight, luminal A–like Results para. 3; eTable 3 2.18 (1.83–2.61) Midpoint 2.185, consistent; not in the abstract
Overweight, luminal B–ERBB2-like Results para. 3; eTable 3 1.83 (1.32–2.55) Midpoint 1.835, consistent; not in the abstract
Obesity, luminal A–like Results para. 3; eTable 3 1.40 (1.02–1.92) Midpoint 1.399, consistent
Obesity, luminal B–ERBB2-like Results para. 3; eTable 3 1.68 (1.01–2.78) Midpoint 1.676, consistent
Abstract value labelled "overweight" Abstract, Results 1.40 (1.02–1.92) Equals only the obesity, luminal A–like cell; matches no overweight cell
Abstract value labelled "obesity" Abstract, Results 1.68 (1.01–2.78) Equals only the obesity, luminal B–ERBB2-like cell
Overweight luminal A–like vs abstract "overweight" Results vs Abstract 2.18 vs 1.40 Ratio of ORs 1.56; excess odds 1.18 vs 0.40, so the abstract shows 34% of it; z = 2.39 for the difference
Overweight luminal B–ERBB2-like vs abstract "overweight" Results vs Abstract 1.83 vs 1.40 Ratio of ORs 1.31; excess odds 0.83 vs 0.40 (48%); z = 1.15
BMI gradient, luminal A–like Results paras. 2–3 2.51 → 2.18 → 1.40 Falls steadily with BMI
BMI gradient, luminal B–ERBB2-like Results paras. 2–3 1.95 → 1.83 → 1.68 Falls steadily with BMI
BMI gradient as the abstract presents it Abstract overweight 1.40, obesity 1.68 Rises from overweight to obesity, which no subtype in the Results does
Significance, overweight and obesity cells Results para. 3 All four CIs exclude 1 z (log OR / SE) = 8.60, 3.60, 2.09, 2.01; unchanged
Fully adjusted model (sensitivity) eTable 7 Overweight 2.18 (1.82–2.61), 1.81 (1.30–2.52); obese 1.41 (1.02–1.93), 1.65 (0.99–2.75) No overweight cell equals 1.40 (1.02–1.92)

Every value in the Results text agrees with eTable 3, and every CI is consistent with its point estimate. The other four current-EPT values in the abstract (2.51, 1.95 and 1.47 for healthy weight, 1.68 for obesity) match Results values for the BMI group they are given under. The only mismatch is the BMI label on the first of the two higher-BMI values.

Figure

The abstract's "overweight" and "obesity" values are both the obesity-row estimates in the Results

Figure 1. On the left (orange) is the abstract's sentence on attenuation, with the value attached to each BMI group as printed. On the right (blue) are the current-EPT odds ratios (95% CI) for women with overweight and obesity from Results paragraph 3, which are identical to the Supplement 1 eTable 3 "Current use" rows. Arrows link each abstract value to the only Results cell that has the same OR and CI. Both arrows end in the obesity row. The abstract's "overweight" value is the obesity, luminal A–like estimate. The shaded overweight row (2.18 and 1.83) is not reported anywhere in the abstract.

Current-EPT odds ratios by BMI group: abstract values vs Results text

Figure 2. Odds ratios with 95% CIs for current EPT use vs never use, on a log axis with a thin reference line at OR = 1. Blue: values from the Results text and eTable 3 (circles, luminal A–like; squares, luminal B–ERBB2-like). Orange diamonds: the abstract's values, drawn under the BMI group the abstract names. In the healthy-weight and obesity groups each orange interval repeats a blue one. In the overweight group the abstract's interval (1.02–1.92) matches neither overweight estimate. It reproduces the obesity, luminal A–like interval one group lower. The blue luminal A–like estimates fall steadily from 2.51 to 2.18 to 1.40.

Why it matters

The BMI stratification is central to how the paper frames its EPT findings: the Key Points and Conclusions stress associations "particularly in participants with healthy weight", and the Discussion describes the luminal A–like and luminal B–ERBB2-like associations as "consistent across BMI groups, albeit attenuated with greater adiposity". The abstract is the only part of the paper that most readers, and most citing articles, see. A reader who relies on it would conclude that among women with overweight, current EPT use is associated with an OR of about 1.40. By the paper's own estimates the overweight luminal A–like OR is 2.18. That is roughly three times the excess odds (1.18 vs 0.40), and the difference is larger than sampling error alone would plausibly produce (z ≈ 2.4). The mislabeling also distorts the dose-response picture by BMI: the abstract's numbers rise from overweight (1.40) to obesity (1.68), while the full results fall steadily with BMI for both subtypes. Because neither value in the sentence is tied to a subtype, a reader also cannot tell that the two numbers refer to different tumor subtypes.

The consequences are limited. All four overweight and obesity estimates are above 1 with CIs that exclude 1, so the abstract's qualitative statement ("attenuated but remained") is true for both BMI groups. The title, Key Points, abstract Conclusions, body Results, Discussion, Figure 1 and the supplement are correct. The estrogen-only therapy and oral contraceptive findings, and the heterogeneity tests, are not affected. The error is a misreported secondary estimate in the abstract, not a change to any headline conclusion.

Explanations considered

The pattern fits a mislabeled sentence in the abstract: the two obesity-row values were placed after "overweight" and "obesity" in place of an overweight value and an obesity value for the same subtype. Nothing in the paper shows how this happened.

Status

As of 2026-10-23:

Sources: publisher full text; PMC12235495; Europe PMC REST full-text XML and supplementary files for PMC12235495; Crossref REST API for doi:10.1001/jamanetworkopen.2025.19236.

Suggested correction

Abstract, Results. Replace "These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78])." with:

These associations were attenuated but remained for individuals with overweight (luminal A–like: OR, 2.18 [95% CI, 1.83-2.61]; luminal B–ERBB2-like: OR, 1.83 [95% CI, 1.32-2.55]) or obesity (luminal A–like: OR, 1.40 [95% CI, 1.02-1.92]; luminal B–ERBB2-like: OR, 1.68 [95% CI, 1.01-2.78]).

If word limits require a shorter sentence, the luminal A–like values alone (overweight 2.18 [1.83-2.61]; obesity 1.40 [1.02-1.92]) would give the BMI gradient correctly. All values are those already given in the Results text and in Supplement 1 eTable 3. No other part of the paper needs to change.